Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
Recruiting · NCT06742021 · Interventional (participants receive a specific treatment) · Lead sponsor: Yunnan Cancer Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
What this trial is about
This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Tumor size greater than 2 cm
- Age between 18 and 75 years
Exclusion criteria
- Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
- Allergy to gadolinium contrast agents
- Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Where it is running
1 location listed.
- Yunnan Cancer Hospital - Kunming, Yunnan, China